1. Ortega-Loubon, C, Fernández-Molina, M, Singh, G, Correa, R. Obesity and its cardiovascular effects. Diabetes Metab Res Rev. 2019;35(4):e3135.
Google Scholar | Crossref | Medline2. Horwich, TB, Fonarow, GC, Clark, AL. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis. 2018;61(2):151–156.
Google Scholar | Crossref | Medline3. Güder, G, Frantz, S, Bauersachs, J, et al. Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors. Circ Heart Fail. 2009;2(6):563–571.
Google Scholar | Crossref | Medline4. Davos, CH, Doehner, W, Rauchhaus, M, et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail. 2003;9(1):29–35.
Google Scholar | Crossref | Medline | ISI5. Lavie, CJ, Osman, AF, Milani, RV, Mehra, MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol. 2003;91(7):891–894.
Google Scholar | Crossref | Medline | ISI6. Cicoira, M, Maggioni, AP, Latini, R, et al. Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial. Eur J Heart Fail. 2007;9(4):397–402.
Google Scholar | Crossref | Medline7. Mogensen, UM, Jhund, P, Køber, L, et al. Abstract 17986: Is there really an ‘obesity paradox’ in heart failure? An analysis of PARADIGM-HF. Circulation. 2016;134(suppl 1):A17986.
Google Scholar8. Calle, EE, Thun, MJ, Petrelli, JM, Rodriguez, C, Heath, CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341(15):1097–1105.
Google Scholar | Crossref | Medline | ISI9. Allison, DB, Gallagher, D, Heo, M, Pi-Sunyer, FX, Heymsfield, SB. Body mass index and all-cause mortality among people age 70 and over: the longitudinal study of aging. Int J Obes Relat Metab Disord. 1997;21(6):424–431.
Google Scholar | Crossref | Medline | ISI10. Sandhu, RK, Ezekowitz, J, Andersson, U, et al. The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J. 2016;37(38):2869–2878.
Google Scholar | Crossref | Medline11. Tittl, L, Endig, S, Marten, S, Reitter, A, Beyer-Westendorf, I, Beyer-Westendorf, J. Impact of BMI on clinical outcomes of NOAC therapy in daily care—results of the prospective Dresden NOAC registry (NCT01588119). Int J Cardiol. 2018;262:85–91.
Google Scholar | Crossref | Medline12. Proietti, M, Guiducci, E, Cheli, P, Lip, GY. Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials. Stroke. 2017;48(4):857–866.
Google Scholar | Crossref | Medline